NCT00726401已完成2 期
A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 4
- 主要终点
- Preliminary estimates of treatment effect of CVT-E002 in improving quality of life and reducing symptoms
研究概览
简要总结
You are being asked to take part in a research study of COLD-fX, a product designed to boost the immune system. COLD-fX is an extract from the roots of North American ginseng and it may offer some benefit to people with seasonal allergies.
The purpose of the present study is to find out how effective and safe COLD-fX is in improving quality of life and reducing symptoms of seasonal allergies such as hay fever. COLD-fX is not yet approved for treatment of seasonal allergies. We are seeking to enroll 200 participants in the Capital Health region.
详细描述
A randomized, double-blind, placebo-controlled study will be carried out to establish the effects of CVT-E002 200 mg twice daily for 4 weeks in patients with seasonal allergic rhinitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy individuals of both genders aged 12 - 75 years
- •Documented clinical history of seasonal allergic rhinitis for at least 2 years with exacerbations during the study season; and exhibit a positive skin-prick test (wheal diameter at least 3 mm greater than saline control) to one of the regional allergens active during the study season
- •Determined by the investigators that well-controlled mild to moderate asthmatics will not be excluded
- •Daytime nasal symptoms of at least mild-to-moderate severity (cumulative score of at least 42 over a 7-day run-in period)
- •Women of child bearing capacity who agree to use an acceptable form of birth control during the trial (i.e., oral contraception, reliable use of a double-barrier method (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD, or tubal ligation)
- •Willing to adhere to the requirements of the protocol, including availability for follow-up visits
- •Willing and able to sign written informed consent
排除标准
- •Medical conditions:
- •Perennial rhinitis with little or no seasonal flare-ups
- •Rhinitis medicamentosa
- •Non-allergic rhinitis
- •Nasal polyps
- •Severe asthma that is poorly controlled
- •Active tuberculosis
- •Cystic fibrosis
- •Upper respiratory tract infection within the preceding 4 weeks
- •Significant other pulmonary disorders
- •Any ongoing allergen immunotherapy during study or for 6 months prior
- •Malignancy (under active observation or treatment)
- •Unstable cardiovascular disease (physician visit or hospitalization for unstable cardiovascular disease in the last 6 months)
- •Renal abnormalities (serum creatinine known to be > 200 mmol/l)
- •Acute or active chronic liver disease
- •Neurological or psychiatric disease (progressive or currently under treatment)
- •Bleeding disorders
- •Major surgery in the last 6 months or planned surgery over the course of the study
- •Other serious medical conditions
- •Medications:
- •Medications for allergic rhinitis/conjunctivitis, including: antihistamines; oral, parenteral, nasal, and ophthalmic corticosteroids; cromolyn sodium; nedocromil; and intranasal anticholinergics (If the participants agree to stop taking these products prior to study entry and for the duration of the study, they can participate in the study.)
- •Oral or long-acting b-agonists, theophylline, and leukotriene modifiers
- •Medications that can affect nasal or ocular symptoms, including decongestants and anti-inflammatory drugs
- •Allergic rhinitis rescue medications
- •Use of immunosuppressants
- •Hormone replacement therapy
- •Phenelzine
- •Pentobarbital
- •Haloperidol
- •Any other natural health products or dietary supplements, with the exception of vitamins and minerals with dose of > 600 mg/day of vitamin E and containing no vitamin K. Natural health products or dietary supplements include products such as, but not limited to, Echinacea, Ginseng (beverages, foods, extracts, capsules, or tablets), St. John's Wort, Gingko, Glucosamine, Fish Oil supplements, Evening Primrose Oil, Green Tea or other herbal products consumed in the form of a pill or capsule. (If the participants agree to stop taking these products prior to study entry and for the duration of the study, they can participate in the study.)
- •Daily smokers (> 25 cigarettes per day)
- •History of alcohol/drug abuse
- •Suspected substance abuse or dependence active within the preceding 4 weeks
- •Pregnant or breast-feeding women
- •Allergy to ginseng, microcrystalline cellulose, or gelatin
研究组 & 干预措施
1
Active Comparator
干预措施: COLD-fX (Drug)
2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Preliminary estimates of treatment effect of CVT-E002 in improving quality of life and reducing symptoms
时间窗: 4 weeks
次要结局
- Safety and tolerability of CVT-E002(4 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy SubjectsSafety IssuesTolerancePulmonary HypertensionIdiopathic Pulmonary FibrosisNCT05427253Vicore Pharma AB80
已完成
不适用
Impact of a Probiotic Combination on Quality of Life and Symptoms in Peri- and Postmenopausal WomenMenopauseNCT06604234AB Biotics, SA245
终止
2 期
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19COVID-19NCT04362189Hope Biosciences Research Foundation48
终止
4 期
PTSD Prevention Study Examining the Efficacy of Sertraline in Burn VictimsPost-traumatic Stress DisorderNCT02520726University of Utah5
已完成
不适用
Effect of an Immune-boosting Food Supplement on the Severity and Frequency of Pediatric Respiratory Tract InfectionsImmunomodulationRespiratory Tract; Infection, Upper (Acute)NCT06218225Azienda Ospedaliera Universitaria Policlinico "G. Martino"120